CN101926853B - 一种具有降血糖作用的药物组合物、其制备方法及应用 - Google Patents
一种具有降血糖作用的药物组合物、其制备方法及应用 Download PDFInfo
- Publication number
- CN101926853B CN101926853B CN 200910099953 CN200910099953A CN101926853B CN 101926853 B CN101926853 B CN 101926853B CN 200910099953 CN200910099953 CN 200910099953 CN 200910099953 A CN200910099953 A CN 200910099953A CN 101926853 B CN101926853 B CN 101926853B
- Authority
- CN
- China
- Prior art keywords
- mori
- amino acids
- extract
- total
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title abstract description 40
- 239000008280 blood Substances 0.000 title abstract description 40
- 235000000346 sugar Nutrition 0.000 title abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 76
- 229930013930 alkaloid Natural products 0.000 claims abstract description 59
- 238000000605 extraction Methods 0.000 claims abstract description 27
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 8
- 241000218231 Moraceae Species 0.000 claims abstract description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 72
- 235000001014 amino acid Nutrition 0.000 claims description 72
- 239000000284 extract Substances 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000007788 liquid Substances 0.000 claims description 40
- 229910021529 ammonia Inorganic materials 0.000 claims description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- 239000000706 filtrate Substances 0.000 claims description 30
- 206010012601 diabetes mellitus Diseases 0.000 claims description 29
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 26
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000003729 cation exchange resin Substances 0.000 claims description 22
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 20
- 239000003513 alkali Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 239000012535 impurity Substances 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000002250 absorbent Substances 0.000 claims description 7
- 230000002745 absorbent Effects 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 150000003053 piperidines Chemical class 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 235000003969 glutathione Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 2
- 229930004006 tropane Natural products 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 abstract description 21
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 62
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 36
- 239000008103 glucose Substances 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 229960002632 acarbose Drugs 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 108010028144 alpha-Glucosidases Proteins 0.000 description 20
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 18
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 18
- 229920002472 Starch Polymers 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000008107 starch Substances 0.000 description 17
- 235000019698 starch Nutrition 0.000 description 17
- 238000005303 weighing Methods 0.000 description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 16
- 230000001476 alcoholic effect Effects 0.000 description 16
- 238000000703 high-speed centrifugation Methods 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 16
- 239000008108 microcrystalline cellulose Substances 0.000 description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 description 16
- 235000012239 silicon dioxide Nutrition 0.000 description 16
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000002641 glycemic effect Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 230000003292 diminished effect Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 229960003646 lysine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 208000004104 gestational diabetes Diseases 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- -1 γ-An Jidingsuan Chemical compound 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 108010054404 Adenylyl-sulfate kinase Proteins 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- 102400000471 Isomaltase Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 2
- BGMYHTUCJVZIRP-UHFFFAOYSA-N Nojirimycin Natural products OCC1NC(O)C(O)C(O)C1O BGMYHTUCJVZIRP-UHFFFAOYSA-N 0.000 description 2
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000001610 euglycemic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960003468 gliquidone Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical compound OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940127017 oral antidiabetic Drugs 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- URJOZSLMTIRWFW-QGZVFWFLSA-N (4r)-4-(1,3-benzodioxol-5-yl)-5,6-dimethoxy-4,9-dihydro-1h-benzo[f][2]benzofuran-3-one Chemical compound C1=C2OCOC2=CC([C@H]2C3=C(COC3=O)CC3=CC=C(C(=C32)OC)OC)=C1 URJOZSLMTIRWFW-QGZVFWFLSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical class C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- TXFVCCZJUJLARR-UHFFFAOYSA-N 3,4,5-trihydroxy-6-(hydroxymethyl)-1H-pyridin-2-one Chemical compound C(O)C1=NC(=C(C(=C1O)O)O)O TXFVCCZJUJLARR-UHFFFAOYSA-N 0.000 description 1
- YZNNBIPIQWYLDM-NGJCXOISSA-N 3-epi-fagomine Chemical compound OC[C@H]1NCC[C@H](O)[C@@H]1O YZNNBIPIQWYLDM-NGJCXOISSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 1
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102400000320 Glicentin Human genes 0.000 description 1
- 101800002945 Glicentin Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical class C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940086290 acarbose 50 mg Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- BOVGTQGAOIONJV-UHFFFAOYSA-N gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical group Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000004880 oxines Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical compound C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 150000003813 tropane derivatives Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 150000008494 α-glucosides Chemical class 0.000 description 1
Abstract
Description
浓度(mmol/L) | 抑制率 |
77.399 | 94.70% |
38.700 | 89.40% |
19.350 | 80.64% |
9.675 | 68.61% |
4.837 | 54.75% |
2.419 | 40.69% |
1.209 | 27.44% |
0.605 | 11.34% |
浓度(mM) | 抑制率 |
3.067 | 95.05% |
1.534 | 91.34% |
0.767 | 84.81% |
0.383 | 74.91% |
0.192 | 60.27% |
0.096 | 42.81% |
0.048 | 25.28% |
0.024 | 10.29% |
浓度(mg/ml) | 实施例3浸膏 | 实施例4浸膏 | 实施例5浸膏 |
0.5 | 64% | 64% | 60% |
0.25 | 54% | 58% | 54% |
0.125 | 46% | 46% | 42% |
0.063 | 34% | 40% | 32% |
0.032 | 29% | 32% | 18% |
0.016 | 24% | 26% | 20% |
0.008 | 15% | 17% | 13% |
组别 | 给药前血糖值(mmol/L) | 给药后30min血糖值(mmol/L) | 血糖增值(mmol/L) | 血糖峰值的抑制率(%) |
模型对照组 | 3.36±0.60 | 8.99±2.19 | 5.63 | - |
100mg/kg桑白 | 3.54±0.78 | 6.58±0.57* | 3.04 | 46.29% |
皮提取物组 | ||||
200mg/kg桑白皮提取物组 | 3.49±0.45 | 6.07±1.11* | 2.58 | 54.14% |
400mg/kg桑白皮提取物组 | 3.60±0.48 | 4.87±1.36* | 1.27 | 77.49% |
50mg/kg拜唐苹组 | 3.68±0.42 | 4.44±0.75* | 0.76 | 84.13% |
4mg/kg桑枝颗粒组 | 3.34±0.39 | 6.51±0.75* | 3.17 | 45.76% |
组别 | 给糖前(0min)血糖值(mmol/L) | 给糖后(60min)血糖值(mmol/L) | 血糖增值(mmol/L) | 血糖峰值的相对抑制率(%) |
模型对照组 | 22.73±2.55 | 26.14±2.73 | 3.41 | - |
100mg/kg桑白皮提取物组 | 22.96±3.34 | 25.73±2.07 | 2.77 | 18.77 |
200mg/kg桑白皮提取物组 | 22.71±3.50 | 24.87±3.89 | 2.16 | 36.66 |
400mg/kg桑白皮提取物组 | 22.56±2.64 | 24.13±3.12 | 1.57 | 53.96 |
50mg/kg拜唐苹组 | 22.91±2.13 | 23.61±2.62 | 0.7 | 79.47 |
4mg/kg桑枝颗粒组 | 22.06±3.17 | 24.88±3.35 | 2.82 | 17.30 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910099953 CN101926853B (zh) | 2009-06-25 | 2009-06-25 | 一种具有降血糖作用的药物组合物、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910099953 CN101926853B (zh) | 2009-06-25 | 2009-06-25 | 一种具有降血糖作用的药物组合物、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101926853A CN101926853A (zh) | 2010-12-29 |
CN101926853B true CN101926853B (zh) | 2013-08-14 |
Family
ID=43366456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910099953 Active CN101926853B (zh) | 2009-06-25 | 2009-06-25 | 一种具有降血糖作用的药物组合物、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101926853B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103998051A (zh) * | 2011-12-01 | 2014-08-20 | 雀巢产品技术援助有限公司 | 桑属浆果及其避免血糖峰值的用途 |
CN103127232A (zh) * | 2013-03-14 | 2013-06-05 | 赵晓昂 | 桑叶方总提物及其制剂和用途 |
WO2015161448A1 (en) * | 2014-04-22 | 2015-10-29 | Wuhan Ll Science And Technology Development Co., Ltd. | Ornithine-containing or aspartate-containing compositions and the uses thereof |
CN103961395A (zh) * | 2014-05-21 | 2014-08-06 | 吕健军 | 一种植物提取物组合物及其用于调控血糖的方法 |
CN104860871A (zh) * | 2015-06-01 | 2015-08-26 | 赣州华汉生物科技有限公司 | 一种dnj提取纯化的方法 |
CN106420932B (zh) * | 2016-08-31 | 2020-02-18 | 宁波大学 | 一种增加胰岛素敏感性的组合物及其应用 |
CN106420934A (zh) * | 2016-11-29 | 2017-02-22 | 汤臣倍健股份有限公司 | 具有辅助降血糖功效的中药组合物及其制备方法和产品 |
CN107019136A (zh) * | 2017-05-26 | 2017-08-08 | 江苏耐雀生物工程技术有限公司 | 一种具有降血糖功效的固体饮料及其制备方法 |
CN108142811A (zh) * | 2017-12-13 | 2018-06-12 | 佛山市日可威食品科技研究院(普通合伙) | 一种荞麦面条及其制备方法 |
CN108125236A (zh) * | 2017-12-19 | 2018-06-08 | 重庆海田林业科技有限公司 | 桑树浓缩液及其制备工艺 |
CN111388593A (zh) * | 2020-02-06 | 2020-07-10 | 广西中医药大学第一附属医院 | 生桑降糖饮及其制备方法 |
CN113243439A (zh) * | 2021-05-26 | 2021-08-13 | 天津沃土佳商贸有限公司 | 一种桑茶及其制备方法 |
CN114010683A (zh) * | 2021-12-17 | 2022-02-08 | 北京五和博澳药业股份有限公司 | 桑提取物在制备治疗胰腺相关疾病的药物中的应用 |
-
2009
- 2009-06-25 CN CN 200910099953 patent/CN101926853B/zh active Active
Non-Patent Citations (4)
Title |
---|
李季芳,等.桑树资源降血糖主要活性成分的研究进展.《中国现代中药》.2008,第10卷(第10期),第6-7、43页. * |
杨文宇,等.桑树总生物碱分析方法与提取方法的探讨.《时珍国医国药》.2008,第19卷(第5期),第1043-1045页. * |
桑的化学成分和生物活性研究进展;顾关云;《国外医药.植物药分册》;20070228;第22卷(第1期);第12-17页 * |
顾关云.桑的化学成分和生物活性研究进展.《国外医药.植物药分册》.2007,第22卷(第1期),第12-17页. |
Also Published As
Publication number | Publication date |
---|---|
CN101926853A (zh) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101926853B (zh) | 一种具有降血糖作用的药物组合物、其制备方法及应用 | |
KR101493016B1 (ko) | 중약 조성물의 새로운 용도 | |
WO2006098604A1 (en) | Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides | |
CN102258679B (zh) | 一种中药组合物、制备方法及其应用 | |
CN104688822A (zh) | 一种辅助降血糖片及制备方法 | |
WO2020010904A1 (zh) | 一种降三高含片及其制备方法 | |
CN111568948A (zh) | 桑提取物在制备改善胰岛功能药物中的应用 | |
CN1618446A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN104815166B (zh) | 一种治疗糖尿病的中药组合物及其制备和应用 | |
CN105920024A (zh) | 一种含有阿卡波糖治疗糖尿病合并高血压的复方制剂及其制备方法 | |
CN103223016B (zh) | 一种防治糖尿病的人参桑菊组合物 | |
CN101121004B (zh) | 含有胰岛素增敏剂和米格列醇的药物组合物 | |
CN1706281A (zh) | 一种能辅助降血糖、辅助降血脂的保健食品及其制备方法 | |
CN1565467B (zh) | 山茱萸及其提取物在制备α-葡萄糖苷酶抑制剂类药物中的用途 | |
CN102716135A (zh) | 羽扇豆酮在制备预防或治疗糖尿病的产品中的应用 | |
CN106075020A (zh) | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 | |
CN101491605A (zh) | 一种具有降血糖功能的组合物及其制备方法 | |
CN107693555A (zh) | 一种治疗糖尿病的药物及用途 | |
CN103211996A (zh) | 一种治疗糖尿病中药的制备方法 | |
CN109260205B (zh) | 一种汉防己甲素在制备抗糖尿病合并高血压药物中的应用 | |
US10149883B1 (en) | Method of treatment of diabetes-inducing kidney failure | |
CN101537102A (zh) | 一种治疗糖尿病的药食两用组合物及其制备方法 | |
US10322157B2 (en) | Method of treatment of drug-resistance diabetes mellitus | |
CN105535947A (zh) | 一种治疗ⅱ型糖尿病的药物组合物及其制备方法 | |
CN101120969A (zh) | 一种治疗糖尿病及其并发症的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Hu Liyong Inventor after: Zhang Lifeng Inventor after: Sun Lien Inventor after: Wang Guangqiang Inventor before: Hu Liyong Inventor before: Zhang Lifeng Inventor before: Wang Guangqiang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HU LIYONG ZHANG LIFENG WANG GUANGQIANG TO: HU LIYONG ZHANG LIFENG SUN LIEN WANG GUANGQIANG |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20101229 Assignee: GUANGDONG YIHETANG PHARMACEUTICAL CO., LTD. Assignor: Zhejiang Jingxin Pharmaceutical Co., Ltd. Contract record no.: 2015440000337 Denomination of invention: Medicine composition with function of lowering blood sugar level as well as preparation method and application thereof Granted publication date: 20130814 License type: Exclusive License Record date: 20150626 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170927 Address after: Guangdong province Zhongshan City Road 528471 Pearl Shaxi Town, No. 34 Patentee after: GUANGDONG YIHETANG PHARMACEUTICAL CO., LTD. Address before: 312500 No. 800 East Avenue, Chengguan Town, Xinchang County, Zhejiang Patentee before: Zhejiang Jingxin Pharmaceutical Co., Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 528400 Bao Zhu West Road, Shaxi Town, Zhongshan, Guangdong Province, No. 34 Patentee after: Guangdong Shaxi Pharmaceutical Co., Ltd. Address before: 528471 Bao Zhu West Road, Shaxi Town, Zhongshan, Guangdong Province, No. 34 Patentee before: GUANGDONG YIHETANG PHARMACEUTICAL CO., LTD. |